How Immune Globulin Intravenous (Human) Works: Immunomodulating therapy via Fc receptor (FcR) blockade, neutralization of pathogenic autoantibodies (anti-idiotypic effects), and complement cascade inhibition.
Last updated:
March 2026
•
Powered by
Elicit’s AI Research Agent
Quick Summary
Intravenous immunoglobulin (IVIG) is a plasma-derived immunoglobulin G (IgG) therapy prepared from pooled human plasma donations. It is used primarily for humoral immunodeficiency, where the body cannot produce adequate antibodies to fight infections, and it also has immunomodulatory effects in various autoimmune disorders. IVIG works through multiple mechanisms, including Fc receptor blockade on immune cells, anti-idiotypic neutralization of pathogenic autoantibodies, and inhibition of the complement cascade.
Properties
Details
Generic Name
Immune Globulin Intravenous (Human)
Brand Names
PRIVIGEN
Drug Class
Plasma-derived immunoglobulin G (IgG) immunomodulating agent
Primary Target
Fc receptors (FcRs) and complement proteins
Approved Indications
Primary humoral immunodeficiency (PI), idiopathic thrombocytopenic purpura (ITP), chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), pemphigus, Kawasaki disease, prevention of bacterial infections in hypogammaglobulinemia associated with B-cell CLL (specific indications vary by brand)
Development History
Immune-globulin-intravenous-human (IGIV) was not designed by a single company but emerged from a decades-long manufacturing evolution rooted in Cohn cold-ethanol plasma fractionation developed at Harvard Medical School in the early 1940s. The problem with intramuscular immunoglobulin — painful administration, volume constraints, and inability to achieve therapeutic serum IgG trough levels rapidly — drove efforts toward an intravenous formulation. Early Cohn fraction II preparations could not be given IV because aggregated IgG molecules triggered complement activation and anaphylactoid reactions; manufacturers resolved this through pepsin digestion at low pH, then through progressively cleaner approaches including caprylate precipitation and chromatographic purification, which eliminated prekallikrein activator and complement-activating contaminants while preserving intact Fc structure, full IgG subclass distribution, and normal circulating half-life. Modern liquid 10% formulations stabilized at pH 4.25 with glycine or proline represented the decisive advance: they eliminated the lyophilization step, reduced aggregation-related adverse events, and allowed infusion rates impractical with earlier products.
The first FDA approval of an IVIG product for primary humoral immunodeficiency (PI) was granted to [VERIFY: brand name, e.g., Gammagard S/D or Sandoglobulin] in [VERIFY: year, ~1981–1988] under BLA [VERIFY: number] (FDA approval letter: [VERIFY: https://www.accessdata.fda.gov/…]). The pivotal program supporting PI licensure followed FDA guidance standardizing a single-arm, 12-month clinical trial design with a primary endpoint of acute serious bacterial infection (ASBI) rate, requiring the upper bound of the one-sided 99% confidence interval to fall below 1.0 ASBI per patient-year. Across licensed products studied under this design, ASBI rates have consistently been well below 0.1 events per patient-year, with IgG trough levels maintained at 800–1,000 mg/dL across 21- or 28-day dosing schedules.
IGIV's label expanded beyond PI in two major waves. The Kawasaki disease indication — supported by a Cochrane meta-analysis of 16 RCTs showing that a single 2 g/kg dose reduced new coronary artery abnormalities at 30 days — established single-infusion 2 g/kg as standard of care and was incorporated into labeling for multiple brands [VERIFY: approval years by brand]. For chronic inflammatory demyelinating polyneuropathy (CIDP), the pivotal program was the Immune Globulin Intravenous CIDP Efficacy (ICE) trial, a randomized, double-blind, placebo-controlled crossover study in 117 participants — the largest CIDP trial conducted to date at the time — which demonstrated significant improvement in the adjusted INCAT disability scale and showed that maintenance dosing of 1 g/kg every three weeks protected against relapse for up to 48 weeks. The ICE data secured FDA approval of Gamunex (10% caprylate/chromatography-purified IGIV, Talecris) for CIDP in [VERIFY: 2008]. Privigen (IgPro10, CSL Behring) subsequently received a CIDP indication supported by the PRIMA study, a Phase III open-label trial in 28 patients reporting a 60.7% INCAT responder rate at Week 25, followed by the larger PATH study; pooled PRIMA/PATH analysis across 235 subjects confirmed a 71.5% INCAT response rate with a median time to improvement of 4.3 weeks. Current approved indications across the IGIV class span PI, CIDP, ITP, Kawasaki disease, and chronic lymphocytic leukemia with recurrent bacterial infections, with recent label activity focused on optimizing dosing frequency and infusion-rate tolerability.
Detailed Mechanism of Action
Clinical Relevance
Emerging Indications
Neurology
Long COVID Neurological Symptoms / POTS (Phase 2): IVIG's immunomodulatory mechanisms — including neutralization of autoantibodies and cytokines implicated in autonomic dysfunction — provide rationale for its use in Post-Acute Sequelae of SARS-CoV-2 (PASC). The NIH NINDS-sponsored NCT05350774 (IN-PASC) is an active Phase 2 crossover study evaluating IVIG in patients with persistent neurological Long COVID symptoms. Separately, the multi-center RECOVER-AUTONOMIC trial (n=200, active not recruiting) is testing IVIG 2 g/kg monthly for 9 months versus placebo on autonomic dysfunction endpoints including POTS in PASC patients, with primary completion estimated April 2026.
Alzheimer's Disease (Phase 3, terminated/negative): IVIG contains naturally-occurring anti-amyloid-β antibodies that reduce Aβ levels and suppress neuroinflammation, providing a biologic basis for its investigation in Alzheimer's disease. The Phase 3 Gammaglobulin Alzheimer's Partnership (GAP) trial (n=390) failed its primary endpoint, showing no cognitive benefit at the doses tested; however, pre-planned subgroup analyses identified positive signals in APOE-ε4 carriers and moderately impaired patients, leaving open the possibility of a precision-medicine subgroup strategy.
Immunology
Anti-HMGCR Immune-Mediated Necrotizing Myopathy (Phase 2): IVIG neutralizes the pathogenic anti-HMGCR autoantibodies that drive complement-mediated muscle fiber necrosis in statin-associated IMNM. The NIH/NIAMS-supported MIGHT Trial (NCT06599697) is currently recruiting at 5 U.S. sites in a placebo-controlled Phase 2 study of IVIG 2 g/kg every 4 weeks (3 doses) in treatment-naïve anti-HMGCR IMNM patients, with serum creatine kinase change as the primary endpoint. A prior pilot protocol at the University of Washington (NCT04450654) was withdrawn, and this 2024 re-launch represents the current state of the program.
Idiopathic Inflammatory Myopathies — Dermatomyositis (Phase 3, positive readout): IVIG modulates the complement cascade and reduces circulating autoantibodies in inflammatory myopathies including dermatomyositis (DM), which lacks FDA-approved IVIG labeling. The 2022 ProDERM Phase 3 placebo-controlled trial demonstrated significant improvement in muscle and cutaneous manifestations in DM patients treated with IVIG versus placebo; this was the first large prospective RCT to do so and has led to regulatory review activity in several jurisdictions, though U.S. FDA labeling for this specific subtype remains pending as of 2025.
Nephrology
Chronic Active Antibody-Mediated Rejection in Kidney Transplant (Phase 2, positive readout): IVIG reduces donor-specific anti-HLA antibody titers and suppresses B-cell–mediated microvascular inflammation via anti-idiotypic mechanisms. The VIPAR randomized controlled trial published in Kidney International (2025) found that IVIG stabilized allograft histology (CADI score) and eGFR versus no-IVIG over 12 months in 30 patients with biopsy-proven chronic active AMR, the leading cause of death-censored graft loss — a condition with no currently approved therapy.
HLA-Sensitized Kidney Transplant Desensitization (Phase 3): High-dose IVIG neutralizes circulating HLA alloantibodies, permitting crossmatch-negative transplantation in broadly sensitized patients. The INHIBIT trial (NCT04302805), a Phase IIIb pilot, was prematurely terminated for futility at interim analysis after 17 patients, though results suggested 3 rejections in the IVIG-sparing arm vs. zero in the IVIG arm, which does not support IVIG omission in HLA-incompatible transplantation.
Hepatology
Biliary Atresia Post-Portoenterostomy (Phase 1/2, completed): IVIG's anti-inflammatory effects may attenuate the ongoing autoimmune bile duct injury that persists after hepatic portoenterostomy (HPE) in biliary atresia (BA), the most common cause of pediatric liver transplantation. The NIDDK-funded NCT01854827 multi-center Phase 1/2 open-label trial (n=29) completed enrollment and assessed IVIG tolerability, safety, and exploratory bile drainage efficacy over 360 days post-HPE in affected infants; results inform the feasibility of proceeding to a powered efficacy trial.
Pulmonology
Acute Exacerbations of Idiopathic Pulmonary Fibrosis (Phase 2, recruiting): Acute exacerbations of IPF (AE-IPF) are thought to involve aberrant immune activation including complement and autoantibody-driven alveolar injury, providing mechanistic rationale for IVIG. The MERCURION-IPF trial (recruiting in Greece) is evaluating IVIG for treatment of AE-IPF, a devastating complication with no proven therapy and near-universal mortality exceeding 50% at 90 days; recent reviews identify AE-IPF as an emerging IVIG indication based on case series and the drug's safety profile in inflammatory lung disease.
Clinical Trials of Immune Globulin Intravenous (Human)
Phase Design
N Enrolled
Intervention
Indication
Primary Endpoint
Key Result
Status
Trial data synthesized by Elicit's AI research agent from peer-reviewed publications and ClinicalTrials.gov filings.
Immune Globulin Intravenous (Human) Competitive Landscape
This table shows how Immune Globulin Intravenous (Human) compares to other immunoglobulin replacement and immunomodulatory therapies. Each entry breaks down the representative products, their mechanisms, and how they work in the body.
Drug Class
Representative Drug(s)
Primary Molecular Target
Mechanism of Action
Key Efficacy Outcomes
Route & Dosing
Safety / Risk Profile
Key Limitations
Competitive landscape synthesized by Elicit's AI research agent from peer-reviewed pharmacology literature and regulatory filings.
Open Research Questions
How do FCGRT gene polymorphisms modulate IVIg pharmacokinetics and explain variable therapeutic response in autoimmune neurological disease?
Up to 30% of patients with immune-mediated neuropathies fail to respond to IVIg despite adequate dosing, and a growing body of evidence implicates variability in FcRn expression as a key contributor. A 2021 review in Therapeutic Advances in Neurological Disorders found that VNTR3/2 polymorphisms in FCGRT may affect the duration of infused IgG in circulation and IVIg effectiveness in GBS, CIDP, and multifocal motor neuropathy, raising the question of whether genotype-guided super-dosing or adjunctive FcRn inhibition could rescue non-responders.
What immunological and molecular biomarkers reliably predict individual response to IVIg before or early after treatment initiation?
Identifying responders prospectively would spare non-responders from costly, supply-constrained therapy while enabling timely escalation. A 2019 review in Biomarker Research noted that reliable biomarkers are required to measure disease activity and assess treatment response in CIDP, and a 2025 study in Journal of the Peripheral Nervous System found that regulatory T cell elevation following IVIg is associated with clinical recovery in Guillain-Barré syndrome, though none of these candidate markers has been validated prospectively at scale.
To what extent does IVIg's polyfunctionality - simultaneous Fab-mediated and Fc-mediated mechanisms - vary across disease substrates, and can component-specific formulations replicate full efficacy?
The coexistence of anti-idiotypic, FcγR-blocking, complement-scavenging, and regulatory T cell-expanding effects makes it difficult to attribute efficacy in any given indication to a single pathway. A 2023 review in the Journal of Allergy and Clinical Immunology: In Practice described how IVIG acts as both an effector and a regulatory molecule with polyfunctionality, while earlier mechanistic work raised the unresolved question of whether Fc-fragment multimers or recombinant IgG could substitute for plasma-derived product in inflammatory indications.
What is the optimal IgG trough threshold and dosing frequency to balance efficacy, safety, and supply in secondary antibody deficiency?
Unlike primary immunodeficiency, secondary antibody deficiency lacks international consensus on when to initiate replacement therapy, at what trough level to aim, and whether intravenous or subcutaneous delivery is preferable. A 2025 review in Clinical Reviews in Allergy and Immunology concluded that large-scale multi-centre trials on IVIg vs SCIg replacement among SAD patients are urgently needed, and a 2026 evidence-mapping review found that comparative evidence between different immunoglobulin brands is limited and indirect treatment comparison is not yet feasible.
How does residual infectious burden - particularly gram-negative respiratory pathogens - persist in antibody-deficient patients on IVIg, and what adjunctive strategies can address it?
Even with adequate IgG trough levels, patients with pre-existing bronchiectasis or structural lung disease continue to sustain recurrent infections with organisms poorly targeted by pooled polyclonal IgG. A 2023 cohort study in JACI: Global found that Haemophilus and Pseudomonas species were identified in over 30% and 21% of sputum samples despite immunoglobulin replacement therapy, underscoring the need for trials integrating inhaled antibiotics and pathogen-specific adjuncts alongside IVIg.
Research Immune Globulin Intravenous (Human) with Elicit — Free
This mechanism of action page was generated using Elicit's AI research agent, which synthesizes explanations from peer-reviewed pharmacology literature. Every pathway description and citation is traceable — because in pharmacology, accuracy isn't optional.
Try these searches on Elicit:
Try now